A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Two Sigma Advisers, LP holds 11,300 shares of BCYC stock, worth $232,102. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,300
Previous 30,900 63.43%
Holding current value
$232,102
Previous $625,000 59.04%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.58 - $27.24 $383,767 - $533,904
-19,600 Reduced 63.43%
11,300 $256,000
Q2 2024

Aug 14, 2024

SELL
$20.02 - $24.69 $314,314 - $387,633
-15,700 Reduced 33.69%
30,900 $625,000
Q1 2024

May 15, 2024

SELL
$16.75 - $26.1 $261,417 - $407,342
-15,607 Reduced 25.09%
46,600 $1.16 Million
Q4 2023

Feb 14, 2024

SELL
$13.29 - $22.2 $112,871 - $188,544
-8,493 Reduced 12.01%
62,207 $1.12 Million
Q3 2023

Nov 14, 2023

SELL
$19.9 - $26.25 $1.37 Million - $1.8 Million
-68,700 Reduced 49.28%
70,700 $1.42 Million
Q2 2023

Aug 14, 2023

SELL
$18.95 - $28.67 $919,075 - $1.39 Million
-48,500 Reduced 25.81%
139,400 $3.56 Million
Q1 2023

May 15, 2023

BUY
$20.02 - $31.37 $522,522 - $818,757
26,100 Added 16.13%
187,900 $4 Million
Q4 2022

Feb 14, 2023

SELL
$20.37 - $32.9 $2.06 Million - $3.32 Million
-100,900 Reduced 38.41%
161,800 $4.79 Million
Q3 2022

Nov 14, 2022

SELL
$17.49 - $28.44 $2.67 Million - $4.34 Million
-152,500 Reduced 36.73%
262,700 $6.11 Million
Q2 2022

Aug 15, 2022

BUY
$12.95 - $46.99 $3.71 Million - $13.5 Million
286,400 Added 222.36%
415,200 $6.97 Million
Q1 2022

May 16, 2022

BUY
$40.12 - $59.5 $1.27 Million - $1.88 Million
31,600 Added 32.51%
128,800 $5.65 Million
Q4 2021

Feb 14, 2022

BUY
$41.7 - $61.14 $2.11 Million - $3.09 Million
50,500 Added 108.14%
97,200 $5.92 Million
Q3 2021

Nov 15, 2021

BUY
$27.95 - $44.24 $1.31 Million - $2.07 Million
46,700 New
46,700 $1.94 Million

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $610M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.